New York Attorney General Faces Scrutiny Over Mandate for Transgender Youth Treatment
New York Attorney General Letitia James is facing increasing criticism following her demand that NYU Langone Health reinstate its Transgender Youth Health Program. The program, which offered treatments including puberty blockers and hormone therapies to minors, was discontinued in February following threats from the Trump administration to withhold federal funding. The move has ignited a legal and ethical debate, pitting state authority against federal regulations and raising concerns about the appropriate medical care for transgender youth. The core of the dispute centers on whether the cessation of these treatments constitutes unlawful discrimination, as James alleges, or a responsible response to evolving medical evidence and potential financial repercussions.
The Attorney General’s office issued a letter on February 25th, asserting that NYU Langone’s decision to halt gender-related treatments illegally targeted transgender youth, as similar care options remain available to other adolescents. This action followed a period of escalating tension, triggered by the Trump administration’s efforts to restrict access to gender-affirming care for minors. The situation has drawn the attention of prominent figures, including Dr. Mehmet Oz, who has publicly challenged James’s actions and defended NYU Langone’s decision. The legal battle unfolding in New York highlights a broader national conflict over the rights of transgender youth and the role of government in regulating medical treatment.
Federal Funding and the Trump Administration’s Policy
The catalyst for NYU Langone’s decision to discontinue its Transgender Youth Health Program was the threat of losing federal funding. In 2024, President Donald Trump signed an executive order aimed at “Protecting Children from Chemical and Surgical Mutilation,” seeking to limit gender-transition treatment for individuals under the age of 19. This executive order led to the Department of Health and Human Services (HHS) threatening hospitals with the potential loss of Medicare and Medicaid funding if they continued to provide gender-affirming care to children. Medicare and Medicaid collectively provide nearly half of all US hospital revenue, creating significant financial pressure on institutions like NYU Langone.
The Trump administration’s actions were informed, in part, by growing concerns about the long-term effects of puberty blockers and hormone therapies on developing adolescents. Similar concerns have prompted policy changes in other countries, notably England, where the National Health Service (NHS) published the Cass Report in 2024. The Cass Report raised concerns about the lack of conclusive evidence supporting the benefits of these treatments for minors and highlighted potential harms. These findings contributed to a more cautious approach to gender-affirming care in some parts of the world.
Legal Challenges and State vs. Federal Authority
Attorney General James responded to NYU Langone’s decision by joining 19 other states in suing the Department of Health and Human Services, arguing that the federal government overstepped its authority. Although, the Social Security Act mandates that HHS establish standards of care for facilities participating in Medicare and Medicaid. This legal framework gives HHS significant power over healthcare providers that rely on federal funding. James’s legal challenge attempts to navigate this complex interplay between state and federal regulations.
James is basing her demand on a New York state law prohibiting discrimination based on gender identity or expression. She argues that NYU Langone’s decision violates this law by denying transgender youth access to medically necessary care. However, the interpretation of “medically necessary” is at the heart of the dispute. Critics of gender-affirming care argue that these treatments are not always medically necessary, particularly for adolescents experiencing gender dysphoria and that alternative approaches, such as psychological counseling, should be prioritized. The Attorney General’s office has given NYU Langone until March 11th to comply with her demand, warning of “further action” if the program is not reinstated. NYU News reported on this deadline.
Concerns About “Gender-Affirming Care” and Alternative Approaches
The debate surrounding “gender-affirming care” extends beyond legal and financial considerations to encompass fundamental questions about medical ethics and the well-being of children. Critics argue that the rush to provide puberty blockers and hormone therapies to young people diagnosed with gender dysphoria is premature and potentially harmful. They point to the irreversible nature of some of these treatments and the lack of long-term data on their effects. Concerns have been raised about the potential for regret and the psychological impact of medical interventions on developing identities.
Advocates for gender-affirming care maintain that these treatments can be life-saving for transgender youth, alleviating distress and improving mental health. They emphasize the importance of individualized care and the require to respect the self-determination of transgender individuals. However, even proponents acknowledge that these treatments are not without risks and that careful evaluation and monitoring are essential. The Finnish study referenced in the New York Post suggests a different approach, highlighting the need for comprehensive assessment and support.
NYU Langone’s website now reflects a shift in focus, emphasizing psychological counseling for adolescents and their families. This change suggests a move towards a more cautious and holistic approach to addressing gender dysphoria, prioritizing mental health support over immediate medical intervention. This shift aligns with growing calls for increased emphasis on therapy and counseling as the first line of treatment for young people questioning their gender identity.
The Role of Dr. Mehmet Oz and Public Discourse
Dr. Mehmet Oz has emerged as a vocal critic of Attorney General James’s actions, arguing that children should not be treated as “guinea pigs” and that emerging medical evidence demonstrates the potential harm of these procedures. In a letter to James, Oz questioned the ethical implications of compelling doctors to perform procedures that remain the subject of substantial dispute. His intervention has amplified the debate and brought increased public attention to the issue.
The controversy surrounding gender-affirming care for minors is likely to continue, with legal challenges and policy debates unfolding across the country. The case of NYU Langone and Attorney General James represents a microcosm of this larger national struggle, highlighting the complex ethical, legal, and medical considerations involved. The outcome of this dispute could have significant implications for the future of transgender healthcare in New York and beyond.
As of March 13, 2026, NYU Langone has not reinstated its Transgender Youth Health Program. The Attorney General’s office has not publicly announced its next steps, leaving the future of the program uncertain. Further developments are expected as the legal and political landscape surrounding gender-affirming care continues to evolve. We encourage readers to share their thoughts and engage in respectful discussion on this vital issue in the comments below.